U.S. Markets for Osteoporosis Management Products Forecast to Exceed $9 Billion by...

U.S. Markets for Osteoporosis Management Products Forecast to Exceed $9 Billion by 2010, According to a New Report from Medtech Insight/Windhover Information

IRVINE, Calif.--(Business Wire)--
Currently, approximately 10 million people in the U.S. are
estimated to have osteoporosis, and another 34 million are believed to
have low bone mass, placing them at risk for developing osteoporosis.
Osteoporosis is a natural part of aging; bone mass and density decline
is a major health threat for more than 44 million people in the U.S.
According to a new osteoporosis drug and device products report
produced by Medtech Insight/Windhover Information, this huge and
promising market will experience an increased annual growth rate of
6.6%, from $6 billion in 2005 to more than $9 billion by 2010.

Major topics covered in this report - entitled "U.S. Markets for
Osteoporosis Management Products" - include an overview of biochemical
markers, bone densitometry systems, and hormone replacement and
osteoporosis drugs. Market forecasts are provided for sales of
antiresorptive drugs such as bisphosphonates, calcitonins, estrogen,
and selective estrogen receptor modulators; bone-forming drugs such as
parathyroid hormone and sodium fluoride; combination drugs; and
treatments such as cathepsin K inhibitors, gene therapy, monoclonal
antibodies, selective androgen receptor modulators, and statin drugs.

Companies covered include The Cooper Companies, General Electric
Company, Hologic, Inverness Medical Innovations, Eli Lilly and
Company, Merck & Company, Novartis AG, Procter & Gamble Company,
Quidel Corporation, Roche Holding AG, and Wyeth, among 50 others
covered in this report. The report includes 30 detailed exhibits, 129
pages, and 11 key company profiles. A full table of contents and
ordering information can be viewed on the Medtech Insight website at
http://www.medtechinsight.com/ReportA302.html.

Medtech Insight/Windhover has also recently published a variety of
additional orthopedic and musculoskeletal market analyses, covering
topics such as directed-energy surgical systems, joint replacement,
spinal fusion and dynamic stabilization products, to name a few. You
can view these and many other reports covering 25 high-growth device
specialty areas at http://www.medtechinsight.com/reports.html.

Medtech Insight/Windhover Information, a division of Reed
Elsevier, provides the medical device and healthcare investment
industries with consistent, comprehensive and meticulously researched
market analyses that incorporate strategic vision and a thorough
understanding of competing technologies. For more on the company's
products, services and investment and partnering events, please visit
www.medtechinsight.com.

Medtech Insight, Irvine
Scott Pantel (sales inside the U.S.), 714-847-3540
or Frank Leysen (sales outside the U.S.),
949-453-0071, ext. 305
888-290-2225 (toll-free in the U.S.)
sales@medtechinsight.com

Copyright Business Wire 2008